Category: FACIT Features

FACIT portfolio company Tenomix secures an all-Canadian investment round for colorectal cancer diagnostic

Posted on by Ricky

March 1, 2024 – FACIT congratulates London, Ontario based Tenomix Inc. (“Tenomix”) on successfully reaching a key milestone in closing its latest financing round to help propel the medtech start-up. Tenomix’s bench-top device will save time and costs by automating the process of lymph node identification in resected tissue while providing more accurate cancer staging for better patient care.

FACIT applauds quizartinib approval: a success for leukemia patients and Canadian cancer research translation

Posted on by Ricky

July 24, 2023 – The U.S. FDA announced the approval of quizartinib, an important new therapy for patients with leukemia. This global effort to impact patients in need is to be celebrated while recognizing the contributions from across the Canadian health R&D ecosystem to reach this significant milestone that will now make a difference for patients.

CTRL Therapeutics, a FACIT-backed start-up, raises US$10M to develop autologous cell therapy for patients living with cancer

Posted on by nicole

March 23, 2023 – CTRL Therapeutics (“CTRL”) closed a seed financing round to develop a tumor-infiltrating lymphocyte (TIL) therapy for solid tumours. CTRL is advancing novel, non-invasive and less costly therapies for patients living with cancer.